Clene Inc.

CLNN | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.54

+$0.19 (+4.37%)

At close: Sep 21, 2026, 4:00 PM ET

$4.60

+$0.06 (+1.30%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.37%

(1D)

Rating

Updated: Aug 29, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $58.01M

1D Range

4.43 4.62

52W Range

3.25 13.50

Valuation (TTM)

PE -1.28

PB -2.34

EV/EBITDA -2.51

Valuation (NTM)

Forward PE N/A

Forward PEG -0.03

Price Target $50

Cash Flow

FCF Yield -27.5%

SBC Adj. FCF Yield -39.8%

SBC Impact -44.6%

Margins

Gross Margin -110.2%

Operating Margin -10304.6%

FCF Margin -8103.5%

Growth (CAGR)

Revenue 3Y | 5Y -36.9% | -18.3%

Dil EPS 3Y | 5Y 14.6% | -11.6%

FCF 3Y | 5Y 28.3% | 25.6%

Returns

ROA -171.5%

ROE 215.0%

ROIC -104.5%

Financial Health

Net Debt

$12.67M

Current Ratio 3.07

Interest Coverage -7.05

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nan...

Sector Healthcare

Industry Biotechnology

Employees 78

IPO Date Oct 17, 2018

Website clene.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$50

Upside

+1001.32%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞